Genevieve M. Boland, MD, PhD, FACS is an Associate Professor of Surgery at Harvard Medical School, Section Head of Melanoma/Sarcoma Surgery, and Surgical Director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital.  Her primary clinical focus is on melanoma and cutaneous oncology.

She undertook combined MD/PhD training, completing a PhD in Cell and Tissue Engineering at the National Institutes of Health focusing on signaling pathways in adult, human mesenchymal stem cells. She graduated cum laude from Thomas Jefferson University as a member of the Alpha Omega Alpha medical honor society and completed her general surgical training at Massachusetts General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She is focused on the clinical management of skin cancer patients. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons.

Dr. Boland has received research support from many groups including the American Surgical Association Foundation Fellowship, the Association of Women Surgeons Research Fellowship, the Harvard Catalyst Medical Research Investigator Training Award, the Karin Grunebaum Cancer Foundation Fellowship, the Society of Surgical Oncology, the Melanoma Research Foundation Breakthrough Consortium, the National Institutes of Health, and the Department of Defense. She is Director of the Surgical Oncology Research Laboratories and Director of the Therapeutic Intralesional Program where she is building a portfolio of direct-to-tumor therapies across multiple tumor types. She is also an Associate Member of the Broad Institute of MIT and Harvard. Her laboratory is currently focused on molecular profiling of melanoma, characterization of molecular and immunological changes that occur during immunotherapy, and the identification of circulating biomarkers of cancer.